Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning
Authors
Keywords
-
Journal
Journal of Oncology
Volume 2021, Issue -, Pages 1-13
Publisher
Hindawi Limited
Online
2021-08-28
DOI
10.1155/2021/5523749
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting tumor microenvironment in ovarian cancer: Premise and promise
- (2020) Yuting Jiang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C
- (2020) Anna Mary Steitz et al. Cell Death & Disease
- FAT10 localises in dendritic cell aggresome-like induced structures and contributes to their disassembly
- (2020) Richard Schregle et al. JOURNAL OF CELL SCIENCE
- Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
- (2020) Eleonora Russo et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process
- (2020) Sara Feola et al. Cancers
- TGFBI modulates tumour hypoxia and promotes breast cancer metastasis.
- (2020) Flavia Fico et al. Molecular Oncology
- Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
- (2020) Olivia Le Saux et al. SEMINARS IN CANCER BIOLOGY
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine
- (2019) Stephanie Lheureux et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer
- (2019) Shuguang Zuo et al. Journal of Translational Medicine
- Optimizing panel-based tumor mutational burden (TMB) measurement
- (2019) J Budczies et al. ANNALS OF ONCOLOGY
- The Tumor Microenvironment Innately Modulates Cancer Progression
- (2019) Dominique C. Hinshaw et al. CANCER RESEARCH
- Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
- (2019) Tao Jiang et al. Journal of Hematology & Oncology
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors
- (2019) Nobuhiro Nakazawa et al. ANNALS OF SURGICAL ONCOLOGY
- Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study
- (2019) Minjoung Monica Koo et al. LANCET ONCOLOGY
- Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy
- (2019) Xu Lei et al. CANCER LETTERS
- Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC)
- (2019) Shiyi Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Human Dendritic Cells Express the Complement Receptor Immunoglobulin Which Regulates T Cell Responses
- (2019) Usma Munawara et al. Frontiers in Immunology
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
- (2018) Álvaro de Mingo Pulido et al. CANCER CELL
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
- (2018) Dapeng Hao et al. CLINICAL CANCER RESEARCH
- Phenotype molding of stromal cells in the lung tumor microenvironment
- (2018) Diether Lambrechts et al. NATURE MEDICINE
- Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1
- (2018) Zainab Al Shareef et al. ONCOGENE
- Evolutionary Pressure against MHC Class II Binding Cancer Mutations
- (2018) Rachel Marty et al. CELL
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Development and validation of an immune gene-set based Prognostic signature in ovarian cancer
- (2018) Sipeng Shen et al. EBioMedicine
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis
- (2017) Kyunghee Noh et al. Cell Reports
- Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy
- (2016) Kwang H. Kim et al. Autophagy
- Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
- (2016) K. F. Bol et al. CLINICAL CANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- Dendritic Cells and Cancer Immunity
- (2016) Alycia Gardner et al. TRENDS IN IMMUNOLOGY
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
- (2014) Katarzyna Marta Lisowska et al. Frontiers in Oncology
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Inferring tumour purity and stromal and immune cell admixture from expression data
- (2013) Kosuke Yoshihara et al. Nature Communications
- High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- (2012) Kosuke Yoshihara et al. CLINICAL CANCER RESEARCH
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
- (2011) D. C. Marchion et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started